Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Torrent Pharmaceuticals Ltd.

http://www.torrentpharma.com

Latest From Torrent Pharmaceuticals Ltd.

Generics Industry Fails To Match Last Year’s Growth In First Quarter

The generics industry struggled with the prior-year comparison as it saw an expected decline in revenues in the first quarter of 2021, driven by the global impact of the COVID-19 crisis. As a result, the performance of most companies fell short of the numbers reported in Q1 2020. However, a few managed to contradict the trend by reporting growth, either based on the launch of COVID-related drugs or performance in specific geographies. 

Sales & Earnings Trends

Indian Leaders Begin Unique Collaboration On Molnupiravir

Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India. 

India Coronavirus COVID-19

Torrent Sees Decline In US Sales After Dropping Sartan Portfolio

Torrent Pharma has reported a double-digit drop in its US revenues after discontinuing its sartan portfolio, due to the presence of trace amounts of N-nitrosodimethylamine. The company saw its domestic market grow aided by market share gains in high potential new launches.

India United States

See-Saw: Challenger Natco Is Now Licensee For Lilly’s Baricitinib

Lilly brings challenger Natco into licensee fold for baricitinib in COVID-19, while the Indian firm retracts a compulsory licensing application for the JAK inhibitor, rapidly diffusing a potentially difficult situation for both sides. But will the six other baricitinib licensees in India match the price of Natco’s on-market version?

India Deals
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Distributors
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Unichem Laboratories Ltd.
    • Bio-Pharm, Inc.
UsernamePublicRestriction

Register